4 results
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Primary objective: To determine if a single administration of SRT2379, at multiple dose levels, attenuates the inflammatory response in normal healthy male subjects after exposure to low-dose endotoxin (LPS)Secondary objectives: (1) To determine…
Primary objective: To determine if a single dose of SRT2379 attenuates the inflammatory response in normal healthy male subjects after exposure to low-dose endotoxin (LPS) Secondary objectives: (1) To determine PK of SRT2379 in normal healthy male…
This study has two parts. The purpose of the first part of the study is to investigate if the investigational drug called dostarlimab (also known as TSR-042) in combination with standard chemotherapy (carboplatin and paclitaxel) will improve the…